ArticleFrontiers in immunology2026
Risk prediction of PLA2R-Ab-negative membranous nephropathy: an interpretable multicenter machine learning model.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Approximately 10%-30% patients with biopsy-proven membranous nephropathy (MN) are seronegative for anti-phospholipase A2 receptor antibody (PLA2R-Ab). Only ~5% are truly non-PLA2R MN and are associated with alternative antigens (e.g., THSD7A), while the majority represent false-negative PLA2R-associated MN due to insufficient assay sensitivity. Accurate noninvasive diagnostic tools for this population are lacking. Methods: This multicenter retrospective risk stratification study enrolled 692 PLA2R Ab negative patients in the derivation cohort and 333 patients in an independent external validation cohort. We developed and validated an interpretable VotingSoft machine learning model based on 13 key clinical variables. Results: The model achieved excellent risk stratification performance: AUC 0.878 (95% confidence interval (CI): 0.850-0.903) in five-fold cross-validation, 0.894 (95% CI: 0.854-0.930) in the internal test set, and 0.905 (95% CI: 0.867-0.935) in the external validation cohort. The model showed a specificity of 0.819, sensitivity of 0.764, and negative predictive value of 0.876. Key predictors were PLA2R Ab level, eGFR, age, and serum albumin. Conclusion: This multicenter interpretable machine learning model provides an auxiliary tool for risk stratification of PLA2R-Ab-negative membranous nephropathy (MN) using routine clinical indicators. Its high specificity may facilitate early risk stratification; however, renal biopsy remains the gold standard for definitive pathological diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.